

## Vincasar PFS (vincristine)

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462

(800) 882-4462 (800.88.CIGNA)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this				
Specialty: * DEA, NPI or TIN:		form are completed.*					
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID: * Date of Birth:			Birth:	
Office Fax:			* Patient Street Address:				
Office Street Address:			City	y State Zip		Zip	
City	State	Zip	Patient Phone:				
Urgency:         Standard         Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication requested:          Vincasar PFS 1mg/mL vial       vincristine 1mg/mL vial         Vincasar PFS 2mg/2mL vial       vincristine 2mg/2mL vial							
ICD10:     Dose:       Frequency of therapy:     Duration of therapy:							
Where will this medication be obtained?         Accredo Specialty Pharmacy**         Prescriber's office stock (billing on a medical claim form)         Other (please specify):         **Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822)							
NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557							
Facility and/or doctor dispensing and administering medication:         Facility Name:       State:         Tax ID#:         Address (City, State, Zip Code):							
Is the patient a candidate for Does the physician have an i	Yes 🗌 No 🗌 Yes 🗍 No 🗍						
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?							
Diagnosis related to use:         acute lymphoblastic leukemia (ALL), including pediatric acute         lymphoblastic leukemia         adult T-cell leukemia/lymphoma (ATLL)         AIDS-related B-cell lymphoma         anaplastic glioma         Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)         bone cancer including Ewing Sarcoma         Burkitt lymphoma         Castleman's disease (CD, giant lymph node hyperplasia, angiofollicular lymph node hyperplasia [AFH])         chronic lymphocytic leukemia (CLL)/small lymphocytic         lymphoma (SLL)         diffuse large B-cell lymphoma (DLBCL)         follicular lymphoma (FL)         gastric MALT lymphoma         Gestational Trophoblastic Neoplasia (GTN)         glioblastoma         Hepatosplenic Gamma-Delta T-Cell Lymphoma (HGDTCL)         High-Grade B-Cell Lymphoma			<ul> <li>Merkel cell carcinoma (MCC)</li> <li>neuroendocrine tumors (NET) – pheochromocytoma</li> <li>(PCC)/paraganglioma</li> <li>nodal marginal zone lymphoma (NMZL)</li> <li>nongastric MALT lymphoma</li> <li>ovarian, fallopian tube, or primary peritoneal cancer</li> <li>peripheral T-cell lymphoma (PTCL)</li> <li>pilocytic astrocytoma</li> <li>post-transplant lymphoproliferative disorder (PTLD)</li> <li>primary CNS lymphoma</li> <li>primary cutaneous CD30+ T-cell lymphoproliferative disorder</li> <li>small cell lung cancer (SCLC)</li> <li>soft tissue sarcoma (STS) including rhabdomyosarcoma(RMS)</li> <li>splenic marginal zone lymphoma (SMZL)</li> <li>Squamous Cell Carinoma of the head and neck (SCCHN)</li> <li>including ethmoid sinus, maxillary sinus, very advanced</li> <li>supratentorial astrocytoma/oligodendroglioma</li> <li>T-cell lymphoma – breast implant-associated ALCL</li> <li>thymoma or thymic carcinoma</li> </ul>				

<ul> <li>Histologic Transformation of Marginal Zone lymphoma (MZL)</li> <li>to Diffuse Large B-Cell lymphoma (DLBCL)</li> <li>Hodgkin's lymphoma (HL)</li> <li>Mantle cell lymphoma (MCL)</li> <li>medulloblastoma</li> </ul>	<ul> <li>Waldenström's macroglobulinemia (WM, lymphoplasmacytic lymphoma)</li> <li>Wilms' Tumor</li> <li>other (please specify):</li> </ul>						
Clinical Information: (if DLBCL) Is the drug requested being given every 14 days with rituximab (Rituxan, Ruxience, Truxima), cyclophosphamide, doxorubicin (Hydroxydaunomycin), and prednisone (also known as R-CHOP-14 treatment or dose dense R-CHOP)? Yes No							
(if PTCL) Is your patient using vincristine (Vincasar PFS) as a part of Hyper CVAD alternating with high-dose methotrexate (MTX) and cytarabine? Note: Hyper CVAD consists of hyperfractionated cyclophosphamide, vincristine [Vincasar PFS], doxorubicin [Adriamycin], and dexamethasone.							
<b>Additional Information: (</b> please include disease stage, prior the agents to be used concurrently):	rapy, performance status, and names/doses/admin schedule of any						
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.							
Prescriber Signature:	Date:						
Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.							
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com. v010124							

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005